for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aurobindo Pharma Ltd

ARBN.NS

Latest Trade

672.90INR

Change

-0.65(-0.10%)

Volume

380,143

Today's Range

669.50

 - 

678.00

52 Week Range

620.50

 - 

1,063.90

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
673.55
Open
677.35
Volume
380,143
3M AVG Volume
49.26
Today's High
678.00
Today's Low
669.50
52 Week High
1,063.90
52 Week Low
620.50
Shares Out (MIL)
585.94
Market Cap (MIL)
388,242.90
Forward P/E
12.58
Dividend (Yield %)
0.68

Next Event

Q3 2022 Aurobindo Pharma Ltd Earnings Release

Latest Developments

More

India's Aurobindo Pharma Sept-Quarter Consol Net Profit Falls

Aurobindo Pharma Unit Eugia Gets FDA Nod For Cyclophosphamide Injection

India's Aurobindo Pharma June-Qtr Consol Net Profit Slightly Lower

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.

Industry

Major Drugs

Contact Info

Water Mark Building,, Plot No. 11

Survey no.9, Kondapur, Hitech City

Hyderabad,Telangana

500081

India

+91.40.66725000

https://www.aurobindo.com/

Executive Leadership

K Ragunathan

Non-Executive Independent Chairman of the Board

K. Nityananda Reddy

Vice Chairman of the Board, Whole-time Director

Santhanam Subramanian

Chief Financial Officer

B. Adi Reddy

Compliance Officer, Company Secretary

N. Govindarajan

Managing Director, Executive Director

Key Stats

1.83 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2019

195.6K

2020

231.0K

2021

247.7K

2022(E)

243.7K
EPS (INR)

2019

41.860

2020

48.770

2021

43.010

2022(E)

52.674
Price To Earnings (TTM)
7.45
Price To Sales (TTM)
1.62
Price To Book (MRQ)
1.66
Price To Cash Flow (TTM)
6.13
Total Debt To Equity (MRQ)
20.35
LT Debt To Equity (MRQ)
2.22
Return on Investment (TTM)
23.67
Return on Equity (TTM)
16.17

Latest News

Latest News

Merck drug less effective against moderate COVID - India regulatory source

Merck & Co's experimental antiviral drug molnupiravir has not shown "significant efficacy" against moderate COVID-19, a source with the Drug Controller General of India said.

IN BRIEF: Amgen sues Aurobindo over proposed generic for dialysis patients

Amgen Inc sued generic drugmaker Aurobindo Pharma Ltd in Delaware federal court, alleging in a complaint entered Friday that Aurobindo's planned generic of its drug Parsabiv to treat a parathyroid condition in dialysis patients will infringe its patents.

Aurobindo Pharma to make COVAXX's potential COVID-19 vaccine for India, UNICEF

Aurobindo Pharma Ltd said on Thursday it would make and sell U.S.-based COVAXX's COVID-19 vaccine candidate for supply in India and to the United Nations Children's Fund (UNICEF) under a licensing deal.

BRIEF-Aurobindo Pharma Says 'Form 483' Issued With 9 Observations After USFDA Inspection Of Dayton, New Jersey Plant

* 'FORM 483' HAS BEEN ISSUED WITH 9 OBSERVATIONS AFTER US FDA INSPECTION OF DAYTON, NEW JERSEY PLANT

BRIEF-Aurobindo Pharma March Quarter Consol Profit Rises

* MARCH QUARTER CONSOL NET PROFIT 8.5 BILLION RUPEES VERSUS 5.85 BILLION RUPEES

BRIEF-Aurobindo Pharma Paid Settlement Amount Of 22 Mln Rupees To SEBI

* PAID SETTLEMENT AMOUNT OF 22 MILLION RUPEES TO SEBI FOR ORDER AGAINST CO AND CERTAIN PROMOTERS

BRIEF-Aurobindo Pharma Gets USFDA Approval For Flucytosine Capsules

* AUROBINDO PHARMA LTD SAYS GETS USFDA APPROVAL FOR FLUCYTOSINE CAPSULES

BRIEF-Aurobindo Pharma Says U.S. FDA Determined That Inspection Classification Of Co's Facility Is Voluntary Action Indicated

* U.S. FDA HAS DETERMINED THAT INSPECTION CLASSIFICATION OF CO'S FACILITY IS VOLUNTARY ACTION INDICATED Source text for Eikon: Further company coverage:

BRIEF-Aurobindo Pharma Ltd -Receives USFDA Approval For Fluoxetine Tablets

* AUROBINDO PHARMA LTD -AUROBINDO PHARMA RECEIVES USFDA APPROVAL FOR FLUOXETINE TABLETS Source text for Eikon: Further company coverage:

UPDATE 1-Novartis scraps sale of assets including COVID-19 hopeful to India's Aurobindo

* Cancellation blow to CEO's plan to focus on higher-margin drugs (Adds details, background)

Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod

Novartis AG said on Thursday it had scrapped the sale of its U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd after failing to get approval from a U.S. regulator.

BRIEF-Aurobindo Pharma Ltd -Terminates Agreement To Buy Sandoz US Generic Oral Solids, Dermatology Businesses

* AUROBINDO PHARMA LTD -ANNOUNCES MUTUAL AGREEMENT WITH SANDOZ INC TO TERMINATE AGREEMENT TO BUY SANDOZ US GENERIC ORAL SOLIDS, DERMATOLOGY BUSINESSES

BRIEF-Aurobindo Pharma Says U.S. FDA's VAI Issued On Feb 18 Rescinded

* GETS NOTICE THAT INSPECTION AT UNIT IV BY U.S. FDA STILL OPEN AND UNDER REVIEW

BRIEF-Aurobindo Pharma Gets VAI Status From U.S. FDA For Facility

* AUROBINDO PHARMA LTD -RECEIVED EIR WITH VOLUNTARY ACTION INITIATED STATUS FROM USFDA FOR UNIT 4, INJECTABLE FORMULATION MANUFACTURING FACILITY Source text for Eikon: Further company coverage:

BRIEF-Novartis says Zolgensma delay in Europe, Japan due to manufacturing questions from regulators

* SANDOZ Q3 OPERATING INCOME WAS USD 191 MILLION (-47%, -42% CC) IMPACTED BY CHANGES IN LEGAL SETTLEMENT PROVISIONS, HIGHER NET MANUFACTURING AND SANDOZ TRANSFORMATION RESTRUCTURING EXPENSES AND LOWER DIVESTMENT INCOME

Takeda unit sues Aurobindo to block generic Velcade

A U.S. unit of Japan's Takeda Pharmaceutical Co has sued generic drugmaker Aurobindo Pharma Ltd over its plans to make a cheaper version of Takeda's cancer drug Velcade.

Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the U.S.

A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up